Navigation Links
Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device
Date:10/1/2010

Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device -- JERUSALEM, October 1, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Banking & Financial Services, Health Care & Hospitals, Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries Click to view news release full screen  

Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device

 

JERUSALEM, October 1, 2010 /PRNewswire-FirstCall/ --

- Patented Technology Developed to Prevent Drug-Related Injuries in Hospitals

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, today announced positive developments relating to the production of a prototype of its patented medicinal locking device technology.

The prototype has successfully passed the company's preliminary testing phase. The tests confirm the potential of the prototype to significantly reduce preventable drug-related injuries in hospitals.

The purpose of the patented device is to physically prevent medication administration errors in hospitals. The device includes a syringe locking mechanism that works in concert with a bar-code reader and database system.

The device uses a barcoded system to electronically confirm whether the syringe held by a medical practitioner contains the correct medication and dosage that has been prescribed to a particular patient, before allowing that medication to be physically administered.

"Medication administration errors in hospitals cause 400,000 preventable drug-related injuries and 70,000 deaths each year," said Jacob elhadad, Chief Executive Officer of Medisafe 1 Technologies. "The preliminary tests of the patented locking-device prototype give us tremendous confidence that our product may aid in significantly reducing instances of such injuries."

"As the healthcare industry in the U.S. continues to mandate the usage of safer syringe technologies, including Barcoding Point of Care (BPOC) systems, Medisafe 1 Technologies is well positioned. Factoring the possibility of widespread implementation, the total potential addressable market for Medisafe's patented technologies could exceed $1 billion per year," Elhadad added.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact: JACOB ELHADAD CEO +972-524440000 JACOB.ELHADAD10@GMAIL.COM
'/>"/>

SOURCE Medisafe 1 Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company
2. Medisafe 1 Technologies Finalises Contract to Develop Prototype of the Worlds First Ever Medicinal Syringe-Locking Device
3. Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend
4. Medisafe 1 Technologies Corp Notify Shareholders on FINRAs Approval of the 5-1 Stock Dividend
5. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
6. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
7. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
8. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
9. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
10. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... Dec. 3, 2016 Johnson & Weaver, LLP announces ... purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ... October 31, 2016 (the "Class Period"). Zimmer Biomet ... markets orthopaedic reconstructive products, such as knee and hip reconstructive ... , , ...
(Date:12/4/2016)... highly innovative, personalized cell-based treatment for a high-risk form of the most ... Children,s Hospital of Philadelphia today reported new results ... The physician-scientists presented findings at the annual meeting of the ... Continue Reading ... ...
(Date:12/2/2016)... -- bioLytical Laboratories, un líder mundial en test rápidos de enfermedades ... Test , a los miembros de la Kenya Pharmaceutical Association. ... ... HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton Health ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who ... now take advantage of a cosmetic procedure known as Carbon Dioxide (C02) ... the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Halfway through ... Medicine has provided preventative dental services to more than 15,900 children 5 years old ... 5 LA pledged $38 million over a span of five years to Western University ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
(Date:12/2/2016)... ... ... Advanced Inc., a leading provider of travel therapy and travel nursing across ... Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as Vice ... leadership experience to Advanced Inc. He began his career in finance at Ernst & ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
Breaking Medicine News(10 mins):